Chemotherapy induced transverse leukonychia in children

Authors

  • Asim Yoruk md,

    Corresponding author
    1. From the Department of Pediatrics, Division of Pediatric Hematology-Oncology, SSK Goztepe Educational Hospital, Istanbul, Turkey
    Search for more papers by this author
  • Handan Yukselgungor md

    1. From the Department of Pediatrics, Division of Pediatric Hematology-Oncology, SSK Goztepe Educational Hospital, Istanbul, Turkey
    Search for more papers by this author

  • American trade names of the drugs: Daunorubicin: Cerubidin; Vincristine: Oncovin, Vincasar PFS, Vincristine Sulfate injection; L-Asparaginase: Elspar; Cyclophosphamide: Cytoxan, Neosar; Cytosine arabinoside: Cytarabine, Cytosar-U; Etoposide: VePesid, Toposar, Etoposide for injection; Idarubicin: IDA; 6-Thioguanine: Thioguanine Tabloid; Methotrexate: Methotrexate LPF, Methotrexate Sodium for injection; Ifosfamide: Ifex; Cisplatin: Cisplatin injection, Platinol; Epirubicine: Ellenca.

Correspondence Dr Asim Yoruk, Tutuncu Mehmet Efendi Cad 94/A Senel Kosk, 81060 Goztepe, Istanbul, Turkey. E-mail: mayoruk@superonline.com

Abstract

Transverse white nail banding can be inherited or caused by various diseases and medications, including cancer chemotherapeutic agents, retinoids, tetracyclines, antimalarials, sulfonamides, pilocarpine, cortisone and zidovudine. Neither a specific drug nor classes of cancer chemotherapeutics were associated more frequently than the other with acquired transverse leukonychia in patients with cancer.

Here we report transverse leukonychia in four children with cancer receiving different chemotherapeutic agents.

Ancillary